SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, kkpennies, Honeycomb777, Peter Lynch, NewTrader2017
Search This Board: 
Last Post: 4/28/2017 12:22:48 AM - Followers: 120 - Board type: Free - Posts Today: 1
* shareholders, please consider purchasing product(s)


Awaiting Official Announcement of FDA Approval for FlutiCare

FlutiCare Approval could bring a BILLION DOLLARS in sales annually

REDONDO BEACH, CA--(Marketwired - Jul 12, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, discusses the potential impact of the anticipated FDA ruling on Innovus Pharmaceuticals' (OTCQB: INNV) ANDA filing for FlutiCare™, the company's over-the-counter treatment for allergic rhinitis.

FlutiCare™ is designed to treat non-allergic rhinitis -- better known as "hay fever" or "stuffy nose" -- which affects roughly 50 million Americans each year. While 70% of these individuals use over-the-counter products, more than half are not satisfied with the treatment option, according to an Asthma and Allergy Foundation of America survey, which suggests there's an opportunity for a prescription-strength OTC treatment option to capture market share from category leaders.

As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. The FDA decision is expected in the next several weeks.


The CEO has already signed an agreement for the manufacturing of FlutiCare

Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision

SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles.  Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.


Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. 
where he helped move the company's stock price from
19 Cents to $6.00 !!!
(Uplisted from OTC to NASDAQ)


Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.
President and Chief Executive Officer:

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.

Who are the major players at Innovus Pharma?


Share Structure:

Shares Outstanding:     124.8 Million (as of 3/3/17)   Dr. Damaj owns $23+M shares alone

Profitability expected exiting Q4 2017 !
- 2017 Projected Revenue of $15M (NOT counting FlutiCare), which would be approximately 3x GREATER than 2016. 


Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call

Corporate Presentation November 2016 (8-K  11/1/2016)

Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)

Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products

Major 2016 Accomplishments:



Where can INNV products be seen?


Existing Product Lines @ Innovus Pharma:

Are you looking to boost your brain health?r

** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
INNV News: Initial Statement of Beneficial Ownership (3) 04/24/2017 06:04:55 AM
INNV News: Current Report Filing (8-k) 04/14/2017 06:08:24 AM
INNV News: Securities Registration: Employee Benefit Plan (s-8) 04/12/2017 04:47:16 PM
INNV News: Statement of Changes in Beneficial Ownership (4) 04/03/2017 01:48:17 PM
INNV News: Statement of Changes in Beneficial Ownership (4) 04/03/2017 01:46:57 PM
#8152  Sticky Note Folks- perhaps we should focus on what we Honeycomb777 04/25/17 06:47:17 PM
#7833  Sticky Note Hey true longs - you haven't heard me Honeycomb777 04/15/17 09:42:02 PM
#6430  Sticky Note Innovus Pharma Announces Receipt of Notification to Commercialize kkpennies 03/08/17 04:20:02 PM
#8266   Because I love 85% of 80% of you, Honeycomb777 04/28/17 12:22:48 AM
#8265   And you are still here....HMMMMM & Bravo :) Honeycomb777 04/27/17 11:29:56 PM
#8264   That's all fine because what I am posting Honeycomb777 04/27/17 10:55:02 PM
#8263   To: DrMonkeyGay, Hi-tech Akorn is the Fluticare manufacturer, proof; gi197845 04/27/17 10:05:48 PM
#8262   Yep, i know. DrMonkeyGray 04/27/17 10:01:31 PM
#8261   Some have said a perfect storm of good gi197845 04/27/17 10:01:01 PM
#8260   i will be preparing a 100 point dynamic TrueTrades 04/27/17 10:00:18 PM
#8259   I don't have allergies, but I'm so frustrated, gi197845 04/27/17 09:54:42 PM
#8258   How low will INNV go? Will it be gi197845 04/27/17 09:48:28 PM
#8257   Well I am a true long with 300,000 pharmacyman 04/27/17 09:05:29 PM
#8256   Folks - I may not post too much Honeycomb777 04/27/17 08:19:06 PM
#8255   Well what do you know new recent lows!! They Adrock 04/27/17 07:17:10 PM
#8254   Information to ponder... gi197845 04/27/17 04:43:01 PM
#8253   TT- I didn't know this was the end ShawnP123 04/27/17 04:33:13 PM
#8251   markets closed shawn lol TrueTrades 04/27/17 04:24:59 PM
#8250   bids and asks ShawnP123 04/27/17 04:10:48 PM
#8249   BTW- I believe Trump is right when he ShawnP123 04/27/17 04:09:19 PM
#8248   Honey you've been claiming turning that corner for ShawnP123 04/27/17 04:06:59 PM
#8247   Futurebean- the sell off isn't done. It will ShawnP123 04/27/17 04:02:38 PM
#8246   Thanks, TRUMP. I added another 10K earlier today. Batermere 04/27/17 02:33:43 PM
#8245   Trump, Thanks for your input the time to futurebeaneater 04/27/17 01:56:44 PM
#8244   I just want people to realize the TRUTH TRUMPFORPRES 04/27/17 01:33:57 PM
#8243   my compliments on your deep tinted mirrored sunglasses TrueTrades 04/27/17 11:48:56 AM
#8242   Fluticare approval this summer imo. BooDog 04/27/17 11:47:11 AM
#8241   In all seriousness, The Big Pharms (like other acnyc 04/27/17 11:41:26 AM
#8240   Trump,. Wow this is comical! stockgenius45 04/27/17 11:20:54 AM
#8239   Trump, I was going to rebut your statements futurebeaneater 04/27/17 11:07:33 AM
#8238   FDA has every right to reject if they TRUMPFORPRES 04/27/17 11:00:05 AM
#8237   FDA has every right to reject if they TRUMPFORPRES 04/27/17 11:00:05 AM
#8236   Is it me or is it telling that Honeycomb777 04/27/17 10:49:47 AM
#8235   We should start to turn the corner a Honeycomb777 04/27/17 08:06:51 AM
#8234   Thank You - then using a take or Honeycomb777 04/26/17 06:30:35 PM
#8233   OK Honey, ShawnP123 04/26/17 05:36:23 PM
#8232   Fluticare will not be rejected. If it's identical mongoosevsgt 04/26/17 05:06:00 PM
#8231   Hello Fabio ! Honeycomb777 04/26/17 04:58:08 PM
#8230   Hi Honeycomb. bfabrico 04/26/17 04:29:48 PM
#8229   Hey Shawn - let's do this for once Honeycomb777 04/26/17 04:01:45 PM
#8228   GTTR- like your response. Has logic and possibilities. ShawnP123 04/26/17 03:38:03 PM
#8227   The way the business model is designed, i bfabrico 04/26/17 03:37:27 PM
#8226   Sounds good to me as long as it ShawnP123 04/26/17 03:34:54 PM
#8225   save your breath TrueTrades 04/26/17 03:13:30 PM
#8224   IMO, and shooting high here, I would like GTTTR15 04/26/17 02:23:37 PM
#8223   MOAP, Honey??? I can't wait to see this Batermere 04/26/17 02:23:26 PM
#8222   Let's just see what people think after I Honeycomb777 04/26/17 02:12:43 PM
#8221   GTTR- Couple of things ShawnP123 04/26/17 01:34:13 PM
#8220   Honey-don't ask what about other stocks. It's easy ShawnP123 04/26/17 01:23:33 PM
#8219   I will start to transition to more realistic Honeycomb777 04/26/17 01:02:44 PM
#8218   I will start to transition to more realistic Honeycomb777 04/26/17 01:02:44 PM
#8217   Don't "engage" him and maybe he will go Batermere 04/26/17 12:46:52 PM
#8216   ssssshhhh- had too when Shawn showed me NITE Honeycomb777 04/26/17 12:06:20 PM